Publications by authors named "Elisangela Costa da Silva"
Background: Few studies in routine settings have confirmed the high accuracy of the Xpert MTB/RIF assay for detecting rifampicin resistance (RR) and the first-line probe assay (FL-LPA) for detecting both RR and isoniazid resistance (INHR).
Methods: The performance of Xpert MTB/RIF and MTBDRplus VER 2.0 LPA was evaluated in 180 Mycobacterium tuberculosis samples collected from January 2018 to December 2019 in Rio de Janeiro, Brazil.
The effect of BCG vaccination on infection and antibody levels against SARS-CoV-2-The results of ProBCG: a multicenter randomized clinical trial in Brazil.
Int J Infect Dis
May 2023
Article Synopsis
- - The study aimed to evaluate if the Bacillus Calmette-Guérin (BCG) vaccine could provide immunity against SARS-CoV-2, the virus that causes COVID-19.
- - Conducted in Brazil, the clinical trial involved 264 healthcare workers, comparing the incidence of COVID-19 and immune responses between those who received the BCG vaccine and a placebo.
- - While results showed BCG might offer some protection and increased levels of immunoglobulin G against SARS-CoV-2, the findings were not statistically significant, suggesting more research is needed.
Vascular endothelial growth factor (VEGF) and interleukin-1 receptor antagonist (IL-1Ra) as promising biomarkers for distinguishing active from latent tuberculosis in children and adolescents.
Tuberculosis (Edinb)
May 2022
Since distinguishing pulmonary (PTB) from latent tuberculosis (LTBI) in pediatric patients remains a challenge, we aimed to investigate the efficacy of immune mediators in diagnosing PTB and LTBI in this population. In this cross-sectional study performed with children and adolescents, serum levels of 20 biomarkers were assessed and data were analyzed according to age groups. We included 65 participants (PTB, n = 28 and LTBI, n = 37).
View Article and Find Full Text PDFArticle Synopsis
- TB-SPRINT is a microbead-based assay designed for rapid detection of tuberculosis and multidrug-resistant TB, aiming to improve clinic and research laboratory outcomes.
- The study evaluated TB-SPRINT's performance against established systems, showing its accuracy in detecting rifampicin and isoniazid resistance ranged from 81% to 99%.
- Despite promising results, further enhancements are necessary for TB-SPRINT to meet In Vitro Diagnostics standards, with costs calculated at approximately USD 127.78 for mean cost and USD 109.94 for activity-based costing.